Stock CVM CEL-SCI CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News CEL-SCI Corporation

Equities

CVM

US1508376076

Market Closed - Nyse
Other stock markets
 04:00:00 2024-07-15 pm EDT 		5-day change 1st Jan Change
1.31 USD +2.34% Intraday chart for CEL-SCI Corporation +6.50% -51.84%
Jul. 08 Cel-Sci Appoints Robert Watson Board's Chair MT
Jul. 08 CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cel-Sci Appoints Robert Watson Board's Chair
MT
CEL-SCI Appoints Robert Watson as Chairperson of the Board
BU
CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board
CI
CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell Microcap Value Index
CI
CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index
CI
CEL-SCI Corporation Presents Head & Neck Cancer Data At Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated with Multikine in the Target Population
CI
CEL-SCI Presents Head and Neck Cancer Data at Iddst Annual Congress in Budapest, Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
AQ
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
BU
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
BU
Cel-Sci: Fiscal Q2 Earnings Snapshot
AQ
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
BU
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
CI
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer
AQ
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine
MT
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
BU
CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine
CI
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
CI
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
BU
CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors
CI
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CVM Stock
  4. News CEL-SCI Corporation